Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.

AFFY, AMGN, VRTX, and QCOR Early Briefing and Review

AFFY, AMGN, VRTX, and QCOR Early Briefing and Review Provides Stock Research on Affymax Inc., Amgen Inc., Vertex Pharmaceuticals Inc., and Questcor Pharmaceuticals Inc.

New York City, New York -- (May 01, 2013)

The biotechnology sector is expected to face increasing costs due to the implementation of the Affordable Care Act (ACA). The ACA is the biggest overhaul of the healthcare industry in decades. While the reform is expected to result in rising costs for the biotechnology sector in the next few years, in the long-run the increase in the number of insured individuals will benefit the sector. The biotechnology industry ended mostly lower on Tuesday even as the broad market posted gains. Among the major movers in the sector were Affymax Inc. (NASDAQ: AFFY), Amgen Inc. (NASDAQ: AMGN), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), and Questcor Pharmaceuticals Inc. (NASDAQ: QCOR). StockCall has released free charting and technical research on these aforementioned companies. Register to read these reports at

Affymax Inc.’s shares were among the major losers in the biotechnology sector on Tuesday. The stock closed 2.16% lower at $0.900 on volume of 834,535, extending their losses in the last three trading sessions to over 6.20%. Shares of AFFY have fallen more than 95% so far in 2013. The substantial losses seen hitherto this year are mainly due to the huge losses seen in February. Affymax’s shares are now trading close to their 52-week low of $0.83. Sign up for the free report on AFFY at

Shares of Amgen Inc. also fell sharply in yesterday’s trading session. The stock fell to an intra-day low of $103.85 before finishing the day 2.31% lower at $104.21 on above average volume of 5.48 million. The company’s shares have fallen 4.1% in the last three sessions. The stock has seen a series of lows in the last three sessions which is a bearish signal. The downbeat trend is further confirmed by the stock’s MACD chart. Year-to-date, however, shares of AMGN are still up more than 21.50%, outperforming the S&P 500. AMGN free technical report can be accessed by signing up at

Shares of Vertex Pharmaceuticals Incorporated also struggled on Tuesday after the Cambridge, Massachusetts-based company reported its financial results for the first quarter. The stock traded between $75.96 and $78.04 before finishing the day 1.93% lower at $76.82. Vertex Pharma’s shares have gained more than 83% so far this year mainly on the back of huge gains posted on April 19. However, since the huge rally on April 19, the biotech company’s shares have seen a series of lows. The stock’s MACD chart suggests that market sentiment has turned bearish. Free report on VRTX can be accessed by registering at

Shares of Questcor Pharmaceuticals Inc. rose sharply yesterday even as the biotechnology sector struggled. The stock closed 3.43% higher at $30.74 on above average volume of 2.56 million, taking its gains in the last three sessions to nearly 5%. The company’s shares have seen a series of highs over the past two weeks, which is a bullish signal. The stock has also crossed above its 50-day and 200-day moving averages which further confirms the positive trend. Questcor’s shares are now trading close to $32 resistance level. Year-to-date, the stock has gained more than 16%.Register withStockCall and download the research on QCOR for free at

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

Contact Person:

William T. Knight

Email: [email protected]

Contact Number: (646) 396-9857 (9:00 am EST – 01:30 pm EST)

Rate this press release
0 stars


Add to favourites icon Add to favourites